vir
biotechnology
gsk
announce
global
expansion
phase
study
evaluating
treatment
independent
data
monitoring
committee
recommended
september
study
continue
phase
based
positive
evaluation
safety
tolerability
data
phase
initial
phase
results
may
available
early
end
results
primary
endpoint
expected
first
quarter
current
estimates
january
successful
potential
advance
outpatient
treatment
patient
enrollment
underway
website
live
https
san
francisco
london
globe
newswire
vir
biotechnology
nasdaq
vir
glaxosmithkline
plc
lse
nyse
gsk
today
announced
global
expansion
phase
monoclonal
antibody
efficacy
trial
intent
care
early
study
evaluating
early
treatment
patients
high
risk
hospitalization
also
known
fully
human
severe
acute
respiratory
syndrome
monoclonal
antibody
selected
based
potential
neutralize
virus
kill
infected
cells
provide
high
barrier
resistance
achieve
high
concentrations
lungs
one
major
sites
infection
following
positive
assessment
unblinded
safety
data
portion
trial
independent
data
monitoring
committee
september
registrational
study
expand
globally
additional
sites
north
america
south
america
europe
george
scangos
chief
executive
officer
vir
said
rapid
achievement
important
milestone
reflects
urgency
mobilizing
resources
hope
preventing
worst
consequences
deadly
virus
antibody
characteristics
may
enable
prevent
hospitalization
death
via
multiple
mechanisms
look
forward
continuing
collaborate
gsk
accelerate
hal
barron
chief
scientific
officer
president
r
gsk
said
given
urgent
patient
need
pleased
progressed
studies
phase
trial
six
months
since
announcing
collaboration
vir
believe
neutralizing
antibody
high
barrier
resistance
notable
effector
function
enhanced
delivery
lung
suggest
potential
fight
global
phase
portion
study
assess
safety
efficacy
single
intravenous
infusion
placebo
approximately
participants
globally
patients
treatment
arm
approximately
patients
placebo
arm
primary
efficacy
endpoint
proportion
patients
progression
defined
need
hospitalization
death
within
days
randomization
interim
analyses
planned
evaluate
safety
futility
efficacy
results
may
available
early
end
results
primary
endpoint
expected
first
quarter
current
estimates
january
comet
clinical
development
program
includes
two
additional
planned
trials
one
treatment
hospitalized
patients
another
prevention
symptomatic
infection
companies
also
expect
start
phase
trial
second
half
evaluating
second
investigational
neutralizing
antibody
shares
characteristics
plus
enhanced
effector
function
may
confer
additional
efficacy
treatment
prophylaxis
stimulating
response
monoclonal
antibody
shown
ability
neutralize
live
virus
vitro
vivo
antibody
binds
epitope
shared
also
known
sars
indicating
epitope
highly
conserved
may
make
difficult
resistance
develop
engineered
potential
enhance
lung
bioavailability
extended
monoclonal
antibody
shown
ability
neutralize
live
virus
vitro
antibody
binds
epitope
shared
also
known
sars
indicating
epitope
highly
conserved
may
make
difficult
escape
mutants
develop
engineered
potential
enhance
lung
bioavailability
extended
function
therapeutic
prophylactic
cell
vaccine
vir
gsk
collaboration
april
vir
gsk
entered
collaboration
research
develop
solutions
coronaviruses
including
virus
causes
collaboration
uses
vir
proprietary
monoclonal
antibody
platform
technology
accelerate
existing
identify
new
antibodies
could
used
therapeutic
preventive
options
help
address
current
pandemic
future
outbreaks
companies
leverage
gsk
expertise
functional
genomics
combine
capabilities
crispr
screening
artificial
intelligence
identify
compounds
target
cellular
host
genes
also
apply
combined
expertise
research
coronavirus
vaccines
vir
biotechnology
vir
biotechnology
immunology
company
focused
combining
immunologic
insights
technologies
treat
prevent
serious
infectious
diseases
vir
assembled
four
technology
platforms
designed
stimulate
enhance
immune
system
exploiting
critical
observations
natural
immune
processes
current
development
pipeline
consists
product
candidates
targeting
hepatitis
b
virus
influenza
human
immunodeficiency
virus
tuberculosis
information
please
visit
gsk
gsk
global
healthcare
company
special
purpose
help
people
feel
better
live
longer
information
please
visit
vir
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
words
may
plan
potential
aim
promising
similar
expressions
well
words
expressions
referencing
future
events
conditions
circumstances
intended
identify
statements
statements
based
vir
expectations
assumptions
date
press
release
statements
involves
risks
uncertainties
actual
results
may
differ
materially
statements
statements
contained
press
release
include
statements
regarding
potential
benefits
vir
collaboration
gsk
expected
timing
clinical
study
results
potential
treat
expected
clinical
activity
clinical
trials
ability
function
therapeutic
prophylactic
vaccine
clinical
activity
well
vir
ability
identify
new
antibodies
technologies
well
vir
ability
address
current
pandemic
future
outbreaks
disease
many
factors
may
cause
differences
current
expectations
actual
results
including
unexpected
safety
efficacy
data
results
observed
clinical
trials
challenges
identifying
new
antibodies
challenges
neutralizing
identifying
inhibiting
cellular
targets
difficulties
obtaining
regulatory
approval
challenges
accessing
manufacturing
capacity
clinical
site
activation
rates
clinical
trial
enrollment
rates
lower
expected
changes
expected
existing
competition
delays
disruptions
vir
business
clinical
trials
due
pandemic
geopolitical
changes
external
factors
unexpected
litigation
disputes
factors
may
cause
actual
results
differ
expressed
implied
statements
press
release
discussed
vir
filings
securities
exchange
commission
including
section
titled
risk
factors
contained
therein
except
required
law
vir
assumes
obligation
update
statements
contained
herein
reflect
change
expectations
even
new
information
becomes
available
gsk
cautionary
statement
regarding
statements
gsk
cautions
investors
statements
projections
made
gsk
including
made
announcement
subject
risks
uncertainties
may
cause
actual
results
differ
materially
projected
factors
include
limited
described
item
risk
factors
company
annual
report
form
set
gsk
principal
risks
uncertainties
section
results
impacts
pandemic
registered
england
wales
registered
office
great
west
road
brentford
middlesex
